The study will investigate the effect of niraparib on tumor tissue in chemotherapy naïve,
newly diagnosed, high-grade endometrial cancer patients. Biomarkers of cognate molecular
pathways as well as investigational assays will be used to study the antineoplastic effect of
the drug.